KODK News & Events

Eastman Kodak Company announced the expansion of its pharmaceuticals portfolio with four new regulated products: KODAK Phosphate Buffered Saline 1X in low endotoxin and RNase/DNase/Protease-free formulations, and KODAK Water for Injection in standard and RNase/DNase/Protease-free formulations. All are immediately available for order by U.S. research laboratories, biopharma developers, and contract development and manufacturing organizations, the company said in a statement. Kodak says the new cGMP-compliant pharmaceuticals production facility in Rochester, N.Y. advances the organization's sustainability commitment through energy-efficient lighting and custom process equipment to reduce greenhouse gas emissions, plus a water sterilization system that minimizes consumption and waste.

Reports Q3 revenue $269M vs. $261M last year. "Kodak delivered strong performance in the third quarter, delivering significant year-over-year increases in gross profit and Operational EBITDA while continuing to focus on driving operational excellence," said Jim Continenza, Kodak's Executive Chairman and CEO. "Our AM&C business continued to grow both revenue and profitability and that group's cGMP pharmaceutical manufacturing facility is now certified to manufacture and sell regulated products, with the goal of expanding our product offering over time. More recently, our AM&C unit's film business launched still films, which will be sold directly to distributors, giving Kodak greater control over our participation in the consumer film market and providing distributors, retailers and consumers with more stable pricing and a broader, more reliable supply. We also recently met our obligations to our U.S. pension plan participants as part of our pension reversion plan and established a new pension plan for employees that is identical to active employee benefit features of the prior plan. By managing the process patiently and carefully we have obtained favorable annuity pricing and investment returns, which resulted in the expected reversion amount to increase from $500 million to $600 million. The next step will be to use the surplus assets from the reversion to pay down debt and strengthen our balance sheet. The reversion frees us up to continue accelerating our plan to create a strong, growing Kodak for our employees and shareholders."